Table 5 Baseline, 3rd-month, and 6th-month VAS, HIT-6, and MIDAS measurement results according to MO status
From: Evaluation of the effectiveness of greater occipital nerve blockade in menstrual migraine
MO patients (n = 19) | wMO patients (n = 14) | P values | ||
|---|---|---|---|---|
mean + SD | mean + SD | |||
VAS | Baseline VAS | 9,0 ± 0,9 | 8,4 ± 1,5 | 0,157 |
VAS at the end of 3 month | 4,7 ± 1,6 | 3,1 ± 2,4 | 0,028 | |
Vas at the end of 6 month | 5,5 ± 1,9 | 3,9 ± 2,8 | 0,057 | |
P* | P < 0,001 | P < 0,001 | ||
MIDAS | Baseline MIDAS | 47,0 ± 24,8 | 27,7 ± 15,7 | 0,016 |
MIDAS at the end of 3 month | 18,2 ± 13,1 | 9,5 ± 11,4 | 0,056 | |
MIDAS at the end of 6 month | 15,1 ± 8,0 | 10,5 ± 10,8 | 0,168 | |
p* | P < 0,001 | P < 0,001 | ||
HIT-6 | Baseline HIT-6 | 71,4 ± 12,9 | 59,8 ± 8,4 | 0,007 |
HIT-6 at the end of 3 month | 49,6 ± 9,1 | 42,5 ± 9,0 | 0,034 | |
HIT-6 at the end of 6 month | 53,3 ± 10,3 | 48,5 ± 10,7 | 0,211 | |
p* | P < 0,001 | P < 0,001 |